Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SANA vs CCCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CCCC Captures Overall Composite Edge (57.2 HOLD vs 44.3 HOLD), While SANA Leads 3–2 on Growth & Valuation Pillars

CCCC Overall Winner 6-Pillar Tally: SANA 3 – 2 CCCC (1 Tie) Matrix Metrics: SANA 4 – 4 CCCC

As of Nov 16, 2026, C4 Therapeutics, Inc. (CCCC) captures the overall head-to-head institutional edge over Sana Biotechnology, Inc. (SANA) on higher Unified Composite conviction (57.2/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Options & Positioning), while SANA wins 3–2 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus CCCC at $2.65 (N/M Forward P/E, -315.9% operating margin).

  • Growth vs. Quality Trade-Off: CCCC earns the overall head-to-head edge with a stronger Unified Composite Score (57.2/100 HOLD vs. SANA 44.3/100 HOLD) and 1.46β · 69% Vol risk profile, whereas SANA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SANA vs CCCC
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $602.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68
CCCC NASDAQ Head-to-Head Winner
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.65
-3.99% 1D
Market Cap $363.7M
TTM Revenue $32M
Forward P/E N/M
Beta / 30D Vol 1.46β · 69% Vol
Unified Composite Score
57.2 / 100 HOLD
Tech 35.0 Fund 52.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 37
RSI-14: 37.3 · SMA20: $3.08 · SMA50: $3.11

6-Pillar Scorecard Institutional Category Breakdown (SANA 3 – 2 CCCC)

Columns: Metric · SANA · CCCC
1. Valuation Multiples CCCC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 12.0x
2. Growth & Scale SANA
Revenue Growth (YoY) +0.0% -24.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $32M
Market Cap $602.3M $363.7M
3. Profitability & Quality SANA
Gross Margin N/A 88.8%
Operating Margin 0.0% -315.9%
Net Profit Margin 0.0% -282.2%
Return on Equity (ROE) -79.5% -47.6%
4. Balance Sheet & Cash Flow SANA
Cash Generation (TTM) -$145M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $13M Net Debt (0.30x D/E) $23M Net Debt (0.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CCCC
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 222.6% (25th %ile) 79.8% (3rd %ile)
Put/Call OI Skew 0.61x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SANA (4) vs CCCC (4)
Institutional Metric SANA CCCC Criterion Row Edge
Market Capitalization
Scale
$602.3M $363.7M Larger Scale SANA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -24.6% Higher Growth SANA
Operating Margin (TTM)
Profitability
0.0% -315.9% Higher Margin SANA
Net Profit Margin
Profitability
0.0% -282.2% Higher Margin SANA
Return on Equity (ROE)
Capital Efficiency
-79.5% -47.6% Higher ROE CCCC
52-Week Range Position
Momentum
1% ($2–$5) 28% ($2–$5) Stronger Trend CCCC
Beta / 30D Volatility
Risk Regime
1.82β · 78% Vol 1.46β · 69% Vol Lower Realized Risk CCCC
Unified Institutional Score
Composite Signal
44.3 / 100 (HOLD) 57.2 / 100 (HOLD) Higher Composite CCCC
Trailing 12M Revenue (USD)
Operating Scale
N/A $32M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 88.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 12.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$145M ($13M Net Debt (0.30x D/E)) -$80M ($23M Net Debt (0.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CCCC +13.02 pp
SANA: -17.18% · CCCC: -4.16%
3M Horizon CCCC +11.61 pp
SANA: -48.21% · CCCC: -36.6%
6M Horizon CCCC +20.46 pp
SANA: -38.16% · CCCC: -17.7%
1Y Horizon CCCC +56.79 pp
SANA: -48.63% · CCCC: +8.16%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs CCCC. Trailing 12-month operating profitability (SANA 0.0% vs CCCC -315.9%) and valuation multiples (SANA N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M
CCCC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$32M
Gross Margin88.8%
Op. Margin-315.9%
ROE / Fwd P/E-47.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 222.6%
IV Percentile 25th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CCCC BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CCCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CCCC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $363.7M market capitalization and -315.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SANA vs CCCC Key Questions & Quantitative Answers

As of Nov 16, 2026, C4 Therapeutics, Inc. (CCCC) captures the overall head-to-head institutional edge over Sana Biotechnology, Inc. (SANA) on higher Unified Composite conviction (57.2/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Options & Positioning), while SANA wins 3–2 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus CCCC at $2.65 (N/M Forward P/E, -315.9% operating margin). Growth vs. Quality Trade-Off: CCCC earns the overall head-to-head edge with a stronger Unified Composite Score (57.2/100 HOLD vs. SANA 44.3/100 HOLD) and 1.46β · 69% Vol risk profile, whereas SANA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SANA leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CCCC at -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $32M for CCCC. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCCC.

CCCC screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus CCCC (-47.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SANA carries 222.6% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.